Alaunos Therapeutics
TCRT
94 hedge funds and large institutions have $126M invested in Alaunos Therapeutics in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 32 reducing their positions, and 11 closing their positions.
31% more call options, than puts
Call options by funds: $3.2M | Put options by funds: $2.44M
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
2% more funds holding
Funds holding: 92 → 94 (+2)
31% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 32
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $204M → $126M (-$77.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$862K |
| 2 |
Goldman Sachs
New York
|
+$323K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$308K |
| 4 |
Morgan Stanley
New York
|
+$271K |
| 5 |
Bank of New York Mellon
New York
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.11M |
| 2 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$2.61M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.63M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$588K |
| 5 |
Barclays
London,
United Kingdom
|
-$540K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VFA
101
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$28K | -46 | Closed |
|
|
BRWA
102
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$12.1K | -20 | Closed |
|
103
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$8K | -13 | Closed |
|
|
EA
104
Emerald Advisers
Leola,
Pennsylvania
| – | -$7K | -12 | Closed |
|
|
GT
105
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$2K | -4 | Closed |
|
TCRT Hedge Fund Activity: Q3 2014 in Review
94 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2014, worth a combined $126M — down 38% from $204M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TCRT positions and 11 closed out — a net gain of 3 holders — while 22 added to existing stakes and 32 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $862K. The largest seller was Fidelity Investments, cutting an estimated $4.11M.
- 94 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2014, up from 92 in Q2 2014.
- Funds reported $126M of Alaunos Therapeutics stock for Q3 2014, down 38% quarter-over-quarter.
- 14 funds opened new Alaunos Therapeutics positions in Q3 2014 and 11 closed out, a net change of +3 holders.
- The largest Alaunos Therapeutics buyer in Q3 2014 was Renaissance Technologies, an estimated $862K added.
- The largest Alaunos Therapeutics seller in Q3 2014 was Fidelity Investments, an estimated $4.11M sold.
Based on aggregated 13F filings for Q3 2014.